BTK and B-cell chronic lymphocytic leukemia: While all seven patients had previously been treated with ibrutinib and discontinued ibrutinib due to the progression of CLL, newly acquired BTK mutations occurred in patients with and without baseline BTK C481 mutations; in two of four the patients with pre-existing BTK C481 mutations, the BTK C481 mutation was suppressed during treatment with pirtobrutinib.